Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Alzheimers Dis. 2005 Apr;7(2):125-33; discussion 173-80.

Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease.

Author information

  • 1Department of Pathology, University of Washington School of Medicine, Seattle, WA 98104, USA.

Erratum in

  • J Alzheimers Dis. 2006 Mar;9(1):81-8.

Abstract

Biomarkers to assist in the diagnosis and medical management of Alzheimer disease (AD) are a pressing need. We have employed a proteomic approach, microcapillary liquid chromatography mass spectrometry of proteins labeled with isotope-coded affinity tags (ICAT), to quantify relative changes in the proteome of human cerebrospinal fluid (CSF) obtained from the lumbar cistern. Using CSF from well-characterized AD patients and age-matched controls at 2 different institutions, we quantified protein concentration ratios of 42% of the 390 CSF proteins that we have identified and found differences > or = 20% in over half of them. We confirmed our findings by western blot and validated this approach by quantifying relative levels of amyloid precursor protein and cathepsin B in 17 AD patients and 16 control individuals. Quantitative proteomics of CSF from AD patients compared to age-matched controls, as well as from other neurodegenerative diseases, will allow us to generate a roster of proteins that may serve as specific biomarker panels for AD and other geriatric dementias.

PMID:
15851850
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for IOS Press
    Loading ...
    Write to the Help Desk